Assenagon Asset Management S.A. Sells 560,865 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Assenagon Asset Management S.A. cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating) by 97.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,826 shares of the medical equipment provider’s stock after selling 560,865 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Lantheus were worth $832,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Robeco Institutional Asset Management B.V. grew its position in shares of Lantheus by 30.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 9,430 shares of the medical equipment provider’s stock worth $663,000 after buying an additional 2,197 shares during the last quarter. Veriti Management LLC grew its position in shares of Lantheus by 5.4% in the 3rd quarter. Veriti Management LLC now owns 3,270 shares of the medical equipment provider’s stock worth $230,000 after buying an additional 168 shares during the last quarter. Strs Ohio grew its position in shares of Lantheus by 1.4% in the 3rd quarter. Strs Ohio now owns 22,500 shares of the medical equipment provider’s stock worth $1,582,000 after buying an additional 300 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Lantheus by 33.4% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 75,846 shares of the medical equipment provider’s stock worth $5,333,000 after buying an additional 18,980 shares during the last quarter. Finally, Truist Financial Corp grew its position in shares of Lantheus by 33.3% in the 3rd quarter. Truist Financial Corp now owns 6,652 shares of the medical equipment provider’s stock worth $468,000 after buying an additional 1,660 shares during the last quarter. 97.62% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Up 3.4 %

LNTH stock opened at $53.08 on Monday. The firm’s fifty day simple moving average is $54.39 and its 200-day simple moving average is $67.27. The company has a market capitalization of $3.65 billion, a P/E ratio of 35.62 and a beta of 0.78. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.13 and a quick ratio of 1.98. Lantheus Holdings, Inc. has a 12 month low of $23.51 and a 12 month high of $87.47.

Lantheus (NASDAQ:LNTHGet Rating) last posted its earnings results on Thursday, November 3rd. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.15. Lantheus had a net margin of 13.35% and a return on equity of 37.77%. The firm had revenue of $239.29 million during the quarter, compared to analysts’ expectations of $228.52 million. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 3.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. Jonestrading began coverage on shares of Lantheus in a research report on Thursday, October 6th. They issued a “buy” rating and a $104.00 price objective on the stock. StockNews.com raised shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Friday, November 4th. SVB Leerink began coverage on shares of Lantheus in a research report on Wednesday, November 30th. They set an “outperform” rating on the stock. Finally, Mizuho began coverage on shares of Lantheus in a research report on Wednesday, October 12th. They set a “buy” rating and a $105.00 target price on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, Lantheus has a consensus rating of “Buy” and an average price target of $102.80.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 4,828 shares of the business’s stock in a transaction on Tuesday, October 18th. The shares were sold at an average price of $73.41, for a total value of $354,423.48. Following the completion of the transaction, the chief financial officer now directly owns 126,065 shares in the company, valued at approximately $9,254,431.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Lantheus news, insider Daniel Niedzwiecki sold 3,000 shares of the company’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $59.73, for a total transaction of $179,190.00. Following the completion of the transaction, the insider now directly owns 65,143 shares in the company, valued at $3,890,991.39. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 4,828 shares of the company’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $73.41, for a total transaction of $354,423.48. Following the transaction, the chief financial officer now owns 126,065 shares of the company’s stock, valued at $9,254,431.65. The disclosure for this sale can be found here. Insiders sold a total of 26,332 shares of company stock worth $1,626,090 in the last three months. Company insiders own 1.60% of the company’s stock.

Lantheus Profile

(Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Featured Stories

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTHGet Rating).

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.